Vaxcyte, Inc. (PCVX) Form 8-K — Nov 4, 2026
Vaxcyte reported Q3 2026 results anchored by positive topline data from the OPUS-1 pivotal Phase 3 trial, in which its 31-valent pneumococcal vaccine candidate VAX-31 met all prespecified primary endpoints in 4,047 adults with a safety profile similar to PCV20 and PCV21. The company raised $1.15 billion gross in October 2026 concurrent equity and 1.50% convertible notes offerings, bringing pro forma cash to approximately $3.4 billion, which it says funds the potential U.S. adult launch of VAX-31 and the rest of the pipeline. Q3 net loss widened to $297.1 million from $212.8 million a year ago as R&D spending rose to $270.3 million on Phase 3 and launch-related manufacturing costs.
Key figures
- Guidance
- OPUS-2 and OPUS-3 Phase 3 results expected H1 2027; VAX-31 infant Phase 2 topline data by end of H1 2027; planned BLA submission H1 2028
- Total Assets
- 2989000000
- Ga Expense Q3
- $37.9 million vs $32.4 million prior year
- Pro Forma Cash
- $3.4 billion (including ~$1.1B October 2026 offering net proceeds)
- Rnd Expense Q3
- $270.3 million vs $209.9 million prior year
- Opus1 Enrollment
- 4047
- Convert Notes Coupon
- 1.50%
- Net Loss Q3 Prior Year
- $212.8 million
- Convert Notes Maturity
- October 2032
- Gross Proceeds October2026
- $1.15 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.